The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation

被引:0
|
作者
Rossi, Esther Diana [1 ]
Bizzarro, Tommaso [1 ]
Granja, Sara [2 ,3 ]
Martini, Maurizio [1 ]
Capodimonti, Sara [1 ]
Luca, Emilia [1 ]
Fadda, Guido [1 ]
Lombardi, Celestino Pio [4 ]
Pontecorvi, Alfredo [5 ]
Larocca, Luigi Maria [1 ]
Baltazar, Fatima [2 ,3 ]
Schmitt, Fernando [6 ,7 ,8 ]
机构
[1] Catholic Univ Sacred Heart Rome, Div Anat Pathol, Milan, Italy
[2] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal
[3] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal
[4] Univ Cattolica Sacro Cuore, Div Endocrine Surg, Milan, Italy
[5] Univ Cattolica Sacro Cuore, Div Endocrinol, Milan, Italy
[6] Med Fac Univ, Porto, Portugal
[7] Inst Pathol Mol Immunol Porto, Porto, Portugal
[8] Lab Natl Sante Luxembourg, Luxembourg, Luxembourg
关键词
Liquid-based cytology; Thyroid lesions; PTC; Plump cells; MCTs; BRAF(V600E) mutation; LIQUID-BASED CYTOLOGY; ASPIRATION BIOPSIES; MALIGNANT-MELANOMA; PROGNOSTIC VALUE; BRAF(V600E); CANCER; CELLS; IMMUNOHISTOCHEMISTRY; IMPACT; CD147;
D O I
10.1007/s12020-016-1044-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BRAF (V600E) mutation, usually performed by DNA techniques, is one of the most common diagnostic markers in papillary thyroid carcinoma. Few papers have demonstrated that plump cells (eosinophilic cytoplasms and papillary thyroid carcinoma nuclei) and peculiar sickle-shaped nuclei represent morphological features of BRAF (V600E) on papillary thyroid carcinomas. These features seem to be linked to glycolytic phenotype whereby monocarboxylate transporters 1-4 are hypothesized to have a dominant role as lactate transporters. We investigated the association between these morphological features and monocarboxylate transporters 1 and 4 in 48 cyto-histological samples diagnosed as "positive for malignancy-favoring papillary thyroid carcinoma". These cases were processed with liquid-based cytology and underwent BRAF (V600E) mutational analysis (pyrosequencing) on liquid-based cytology and monocarboxylate transporters immunostaining on histology. The expression of monocarboxylate transporter 1, monocarboxylate transporter 4, glucose trasporter-1 and carbonic anhidrase were scored semi-quantitatively with expression from 0 to 3+ (strong positivity). The 33 mutated and 15 wild type cases showed 100 % cyto-histological concordance. The cytological evaluation revealed plump cells and sickle nuclear shape in 100 % mutated cases. Monocarboxylate transporter 1 yielded 76 % positivity in the mutated cases especially in both the plump cells and sickle-shaped nuclei, whereas the wild types showed 13.3 % positive monocarboxylate transporter 1 (p = 0.00013). Monocarboxylate transporter 4 resulted in 100 % positivity in mutated and 40 % in wild types (p < 0.005). Furthermore, 20 % of the wild types showed weak monocarboxylate transporter 1 nuclear expression associated to a less aggressive behavior. The analysis of glucose trasporter-1 and carbonic anhidrase did not highlight any statistical significance (p > 0.05). This is the first report analyzing the association between monocarboxylate transporter expression and the morphological features of BRAF (V600E) mutated papillary thyroid carcinomas suggesting the possible involvement of lactate in the morphological features.
引用
收藏
页码:379 / 387
页数:9
相关论文
共 50 条
  • [21] Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population
    Brzezianska, Ewa
    Pastuszak-Lewandoska, Dorota
    Wojciechowska, Katarzyna
    Migdalska-Sek, Monika
    Cyniak-Magierska, Anna
    Nawrot, Ewa
    Lewinski, Andrzej
    NEUROENDOCRINOLOGY LETTERS, 2007, 28 (04) : 351 - 359
  • [22] Lack of MAPK activation in papillary thyroid carcinoma with BRAF V600E mutation
    Zuo, Hui
    Nakamura, Yasushi
    Yasuoka, Hironao
    Nakamura, Misa
    Mori, Ichiro
    Miyauchi, Akira
    Kakudo, Kennichi
    CANCER RESEARCH, 2006, 66 (08)
  • [23] Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma
    Rushton, Sarah
    Burghel, George
    Wallace, Andrew
    Nonaka, Daisuke
    HISTOPATHOLOGY, 2016, 69 (03) : 524 - 526
  • [24] BRAF V600E Mutations in Infarcted Thyroid Carcinoma
    Kouba, Erik
    Ford, Andrew
    Brown, Charmaine G.
    Yeh, Chen
    Kim, Hyung-Gyoon
    Siegal, Gene P.
    Manne, Upender
    Eltoum, Isam-Eldin
    LABORATORY INVESTIGATION, 2017, 97 : 327A - 327A
  • [25] BRAF V600E Mutations in Infarcted Thyroid Carcinoma
    Kouba, Erik
    Ford, Andrew
    Brown, Charmaine G.
    Yeh, Chen
    Kim, Hyung-Gyoon
    Siegal, Gene P.
    Manne, Upender
    Eltoum, Isam-Eldin
    MODERN PATHOLOGY, 2017, 30 : 327A - 327A
  • [26] Relationship between BRAF V600E and clinica features in papillary thyroid carcinoma
    Yan, Changjiao
    Huang, Meiling
    Li, Xin
    Wang, Ting
    Ling, Rui
    ENDOCRINE CONNECTIONS, 2019, 8 (07): : 988 - 996
  • [27] The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma
    Lin, Zi-Mei
    Yan, Cao-Xin
    Song, Yue
    Hong, Yu-Rong
    Wen, Qing
    Xu, Yong-Yuan
    Pan, Min-Qiang
    Ye, Qin
    Huang, Pin-Tong
    JOURNAL OF THORACIC DISEASE, 2019, 11 (12) : 5071 - 5078
  • [28] BRAF V600E mutation negative cases tend to lose lamin A expression in papillary thyroid carcinoma
    Moriya, S.
    Tamaki, H.
    Hatori, M.
    Kobayashi, S.
    Nishijima, Y.
    Fujii, T.
    Ikota, H.
    Shirabe, K.
    Yokoo, H.
    Saio, M.
    VIRCHOWS ARCHIV, 2020, 477 : S287 - S288
  • [29] BRAF (V600E) mutation in isthmic malignant thyroid nodules
    Campenni, A.
    Giovanella, L.
    Alibrandi, A.
    Siracusa, M.
    Ruggeri, R. M.
    Baldari, S.
    CLINICAL ENDOCRINOLOGY, 2016, 84 (01) : 152 - 153
  • [30] BRAF V600E MUTATION STATUS AND ASSOCIATED HISTOPATHOLOGY FEATURES IN PAPILLARY THYROID CARCINOMA: A COMPARISON OF NEW CALEDONIA AND AUSTRALIAN POPULATIONS
    Dy, Veronica
    Lie, Triyana
    Woolnough, Catherine
    Tubb, Jessie
    Dubourdieu, Dominique
    Damiens, Viviene
    McLennan, Susan
    Chua, Elizabeth
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 32 - 32